Epstein Secrets

TW launch in 2019 but would see $2/share of upside should MNTA launch at-risk (assuming approval). Links to Notes • Link to TEVA Note • Link to MYL Note • Link to MNTA Note Quick Background on Copaxone 3TW Litigation (from Sumant's note) Copaxone 3TW has new product exclusivity through 1/28/17 and

ew (S58ish) while a negative outcome likely sees 5% downside to around $50/sh (given a Cons already assumes generic competition coming next year). Copaxone Litigation Timeline (from 2O Results Slidedeck) Scenario Analysis — BofAML Daniel Lundquist EFTA00820344 Healthcare Specialist Sales Global Equities Bank of Ameri

TW launch in 2019 but would see $2/share of upside should MNTA launch at-risk (assuming approval). Links to Notes • Link to TEVA Note • Link to MYL Note • Link to MNTA Note Quick Background on Copaxone 3TW Litigation (from Sumant's note) Copaxone 3TW has new product exclusivity through 1/28/17 and

ew (S58ish) while a negative outcome likely sees 5% downside to around $50/sh (given a Cons already assumes generic competition coming next year). Copaxone Litigation Timeline (from 2Q Results Slidedeck) Scenario Analysis — BofAML EFTA00820353 Daniel Lundquist Healthcare Specialist Sales Global Equities The power of

19 but would see $2/share of upside should MNTA launch at-risk (assuming approval). Links to Notes EFTA00665657 • Link to TEVA Note • Link to MYL Note • Link to MNTA Note Quick Background on Copaxone 3TW Litigation (front Sumant's note) Copaxone 3TW has new product exclusivity through 1/28/17 an

le a negative outcome likely sees 5% downside to around $50/sh (given a Cons already assumes generic competition coming next year). EFTA00665659 Copaxone Litigation Timeline (from 2Q Results Slidedeck) Scenario Analysis — BofAML Daniel Lundquist Healthcare Specialist Sales Global Equities Bank of America Merrill Lync